This week we are delighted to invite nominations from individuals interested in joining our Board. Nominations must be received by close of business on Wednesday 07 September 2016.

This year, there are five places up for election – four for ‘Corporate’ members and one for ‘Other’ members. The elections will take place during September, and pending approval at the AGM on 20 October 2016, those elected will join the BIA’s Board commencing 1 January 2017 and will serve a three year term.

Please submit any nominations by the end of the day on Wednesday 7 September, together with a photograph and brief biography. These should be sent to Nick Gardiner, Company Secretary (please CC Jessica Gray: If you have any questions, please contact Nick.

The UK EU Life Sciences Transition Programme is making quick progress during the summer.  We are now in week five of the nine week project.  Five of the six working groups have now taken place and the final working group on people will take place this week.  Next week the Co-Chairs of the Working Groups will come together for  a strategy meeting.

Last Friday members of the BIA Board took part in a senior level event with senior ABPI members and PwC focusing on the advantages of leaving the EU.

In conjunction with the ABPI we will be holding another members townhall on the 18th August on the Transition Programme.  The meeting is open to all ABPI and BIA members and will provide the opportunity to hear about the processes and progress of the work, and to ask any questions that you may have.  Please confirm your attendance by completing the online form.  Please note that is event is for ABPI and BIA members only.  We will also be holding a webinar, open to stakeholders and members, on 2 September.

This week the European Medicines Agency (EMA) published its final report on the adaptive pathways pilot. The adaptive pathways approach is a scientific concept of product development and data generation intended for medicines that address patients’ unmet medical needs. The pilot project, which ran from March 2014 to July 2016, showed that adaptive pathways can bring stakeholders together from regulators, health technology assessment (HTA) bodies, healthcare professionals and patients, and reach agreement on a prospective plan to evidence generation.

The pilot also helped to identify a number of aspects for further reflection; these include the increased involvement of patients in the selection of candidates for adaptive pathways, the definition of methodologically sound strategies of real-world evidence collection to support the assessment of both efficacy and effectiveness and the potential involvement of payers to provide input on pricing strategies.

The BIA will be participating in the December workshop organised by the EMA to gather stakeholders’ views and proposals. The adaptive pathways pilot featured in our sixth annual joint BIA/MHRA conference on Accelerated Development and Access to Innovative Medicines for Patients, held on 4 May. The full report can be downloaded from the conference website.

Best, Steve